215 related articles for article (PubMed ID: 16442844)
1. Levosimendan therapy in decompensated chronic heart failure: favourable haemodynamic and neurohormonal effects but for how long?
Parissis JT; Farmakis D; Kremastinos DT
Eur J Heart Fail; 2006 Mar; 8(2):215; author reply 218. PubMed ID: 16442844
[No Abstract] [Full Text] [Related]
2. Levosimendan reduces plasma amino terminal proBNP in patients with decompensated heart failure.
Mueller T; Gegenhuber A; Haltmayer M
Int J Cardiol; 2005 Oct; 104(3):355-6; author reply 357-8. PubMed ID: 15950299
[No Abstract] [Full Text] [Related]
3. Effects of levosimendan versus dobutamine on inflammatory and apoptotic pathways in acutely decompensated chronic heart failure.
Adamopoulos S; Parissis JT; Iliodromitis EK; Paraskevaidis I; Tsiapras D; Farmakis D; Karatzas D; Gheorghiade M; Filippatos GS; Kremastinos DT
Am J Cardiol; 2006 Jul; 98(1):102-6. PubMed ID: 16784930
[TBL] [Abstract][Full Text] [Related]
4. [Levosimendan for treatment of heart failure].
Yasumura Y
Nihon Rinsho; 2007 May; 65 Suppl 5():169-72. PubMed ID: 17571380
[No Abstract] [Full Text] [Related]
5. Levosimendan.
Kamath SR; Jaykumar I; Matha S
Indian Pediatr; 2009 Jul; 46(7):593-6. PubMed ID: 19638658
[No Abstract] [Full Text] [Related]
6. Oral levosimendan in patients with severe chronic heart failure --the PERSIST study.
Nieminen MS; Cleland JG; Eha J; Belenkov Y; Kivikko M; Põder P; Sarapohja T
Eur J Heart Fail; 2008 Dec; 10(12):1246-54. PubMed ID: 18945637
[TBL] [Abstract][Full Text] [Related]
7. Clinical significance of acute neurohormonal response after levosimendan treatment.
Giannakoulas G; Giannoglou G; Vassilikos V; Martiadou K; Kalpidis P; Parharidis G; Louridas G
Am J Cardiol; 2006 Oct; 98(8):1123-4. PubMed ID: 17027590
[No Abstract] [Full Text] [Related]
8. Natriuretic peptide-guided levosimendan therapy for heart failure: a promising new approach.
Giamouzis G; Giannakoulas G; Tsarpalis K; Agha SA; Georgiopoulou V; Kalogeropoulos A; Karvounis H; Butler J
Int J Cardiol; 2008 Aug; 128(1):91-3; author reply 94-6. PubMed ID: 18495268
[No Abstract] [Full Text] [Related]
9. Levosimendan and prostaglandin E1 for uptitration of beta-blockade in patients with refractory, advanced chronic heart failure.
Berger R; Moertl D; Huelsmann M; Bojic A; Ahmadi R; Heissenberger I; Pacher R
Eur J Heart Fail; 2007 Feb; 9(2):202-8. PubMed ID: 16859992
[TBL] [Abstract][Full Text] [Related]
10. Effects of levosimendan on right ventricular function in patients with advanced heart failure.
Parissis JT; Paraskevaidis I; Bistola V; Farmakis D; Panou F; Kourea K; Nikolaou M; Filippatos G; Kremastinos D
Am J Cardiol; 2006 Dec; 98(11):1489-92. PubMed ID: 17126656
[TBL] [Abstract][Full Text] [Related]
11. Levosimendan and plasma BNP levels: do inflammatory cytokines regulate BNP in chronic decompensated heart failure?
McLachlan CS; Mossop P
Eur J Heart Fail; 2006 Mar; 8(2):216-7; author reply 218. PubMed ID: 16488367
[No Abstract] [Full Text] [Related]
12. Duration of the haemodynamic action of a 24-h infusion of levosimendan in patients with congestive heart failure.
Lilleberg J; Laine M; Palkama T; Kivikko M; Pohjanjousi P; Kupari M
Eur J Heart Fail; 2007 Jan; 9(1):75-82. PubMed ID: 16829185
[TBL] [Abstract][Full Text] [Related]
13. Effects of levosimendan on circulating pro-inflammatory cytokines and soluble apoptosis mediators in patients with decompensated advanced heart failure.
Parissis JT; Adamopoulos S; Antoniades C; Kostakis G; Rigas A; Kyrzopoulos S; Iliodromitis E; Kremastinos D
Am J Cardiol; 2004 May; 93(10):1309-12. PubMed ID: 15135713
[TBL] [Abstract][Full Text] [Related]
14. A struggle to SURVIVE: to abandon or not to abandon levosimendan?
Butler J; Giamouzis G; Giannakoulas G
Cardiovasc Drugs Ther; 2007 Oct; 21(5):401-2. PubMed ID: 17701453
[No Abstract] [Full Text] [Related]
15. Levosimendan reduces plasma B-type natriuretic peptide and interleukin 6, and improves central hemodynamics in severe heart failure patients.
Kyrzopoulos S; Adamopoulos S; Parissis JT; Rassias J; Kostakis G; Iliodromitis E; Degiannis D; Kremastinos DT
Int J Cardiol; 2005 Mar; 99(3):409-13. PubMed ID: 15771921
[TBL] [Abstract][Full Text] [Related]
16. [Levosimendan--an alternative to conventional inotropic treatment of patients with acute heart failure?].
Rasmussen T; Schmidt H
Ugeskr Laeger; 2006 Jan; 168(3):261-5. PubMed ID: 16430807
[TBL] [Abstract][Full Text] [Related]
17. Levosimendan: a review of its use in the management of acute decompensated heart failure.
Innes CA; Wagstaff AJ
Drugs; 2003; 63(23):2651-71. PubMed ID: 14636085
[TBL] [Abstract][Full Text] [Related]
18. Effects of levosimendan on markers of kidney function in patients with acutely decompensated heart failure and renal impairment.
Rafouli-Stergiou P; Parissis JT; Farmakis D; Bistola V; Frogoudaki A; Vasiliadis K; Ikonomidis I; Paraskevaidis I; Kremastinos D; Filippatos G; Lekakis J
J Cardiovasc Med (Hagerstown); 2017 Oct; 18(10):771-773. PubMed ID: 25643197
[No Abstract] [Full Text] [Related]
19. Intravenous levosimendan vs. dobutamine in acute decompensated heart failure patients on beta-blockers.
Bergh CH; Andersson B; Dahlström U; Forfang K; Kivikko M; Sarapohja T; Ullman B; Wikström G
Eur J Heart Fail; 2010 Apr; 12(4):404-10. PubMed ID: 20335355
[TBL] [Abstract][Full Text] [Related]
20. Medical support and surgery of the failing heart: levosimendan.
Toller W; Knez I
Scand J Surg; 2007; 96(2):121-4. PubMed ID: 17679353
[No Abstract] [Full Text] [Related]
[Next] [New Search]
